Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.IDRA · Entity 110652 | Director | June 23, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-06-23 | Direct | 26,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 26,000 · Balance 26,000 F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy.
F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
JUNIPER PHARMACEUTICALS INC
Report date August 14, 2018 · Filed August 15, 2018
Section 16 reporting ended · disclosed 2018-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 1
1 source rowRow 1 · 2018-08-14 · Disposition to issuer · Disposed 36,109 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2: Includes 8,910 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 8,910 restricted stock units was cancelled in exchange for the Offer Price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
F2: Includes 8,910 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 8,910 restricted stock units was cancelled in exchange for the Offer Price.
PALISADE BIO, INC.
Report date February 08, 2024 · Filed February 13, 2024
Section 16 reporting ended · disclosed 2024-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01SEC Table I · non-derivative | Direct | 12,862 |
Last balance in matching sequence
After 2024-02-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-02-08 · Exercise / conversion · Acquired 6,980 · Balance 7,042 F1: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. Row 2 · 2024-02-08 · Exercise / conversion · Acquired 5,820 · Balance 12,862 F1: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. F2: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-08 · Exercise / conversion · Disposed 6,980 · Balance 0 F3: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding. F5: Each restricted stock unit represents the right to receive one share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-08 · Exercise / conversion · Disposed 5,820 · Balance 0 F4: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding. F5: Each restricted stock unit represents the right to receive one share of common stock. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-06-11 | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-08 · Exercise / conversion · Disposed 9,580 · Balance 0 F6: Each option represents the right to purchase one share of common stock at the exercise price. F7: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-06-11 | Direct | 9,580 |
Reported balance
After 2024-02-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-08 · Exercise / conversion · Acquired 9,580 · Balance 9,580 F6: Each option represents the right to purchase one share of common stock at the exercise price. F7: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-11-21 | Direct | 0 |
Reported balance
After 2024-02-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-08 · Exercise / conversion · Disposed 6,880 · Balance 0 F6: Each option represents the right to purchase one share of common stock at the exercise price. F8: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-11-21 | Direct | 6,880 |
Reported balance
After 2024-02-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-08 · Exercise / conversion · Acquired 6,880 · Balance 6,880 F6: Each option represents the right to purchase one share of common stock at the exercise price. F8: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F2: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F3: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding.
F4: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding.
F5: Each restricted stock unit represents the right to receive one share of common stock.
F6: Each option represents the right to purchase one share of common stock at the exercise price.
F7: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.
F8: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · derivative · entry 8 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F8 · security: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · derivative · entry 7 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F8 · security: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 9,580 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · derivative · entry 6 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,580 Underlying: Common Stock · 9,580 shares Expires 2033-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F7 · security: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock Options · Derivative | 9,580 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · derivative · entry 5 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,580 shares Expires 2033-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each option represents the right to purchase one share of common stock at the exercise price. F7 · security: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · derivative · entry 4 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding. F4 · derivative.exercise_price: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of common stock. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 6,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · derivative · entry 3 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,980 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding. F3 · derivative.exercise_price: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of common stock. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · nonDerivative · entry 2 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. F2 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 20:08 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 6,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-006047 · ownership.xml · nonDerivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-23-042659 · ownership.xml · derivative · entry 2 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-042659 · ownership.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 5,820 shares Expires not disclosed F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F3 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 22:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 9,580 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-23-021128 · ownership.xml · derivative · entry 2 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,580 Underlying: Common Stock · 9,580 shares Expires 2033-06-11 F1 · security: Represents partial compensation for services rendered as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from the Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 1,880 restricted stock units and 2,580 common stock purchase options as a discretionary grant. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 22:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-021128 · ownership.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,980 Underlying: Common Stock · 6,980 shares Expires not disclosed F1 · security: Represents partial compensation for services rendered as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from the Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 1,880 restricted stock units and 2,580 common stock purchase options as a discretionary grant. F3 · security: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 16:30 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001415889-22-006939 · form4-06272022_040607.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-23 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| November 18, 2021 Filed Feb 10, 2022 23:07 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (right to buy) · Derivative | 48,340 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-008565 · doc4.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,340 Underlying: Common Stock · 48,340 shares Expires 2032-11-17 F1 · derivative.exercise_date: 25% of the shares of Common Stock subject to the Option shall vest on each quarterly anniversary of the grant date over a one-year period. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:05 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001415889-21-002916 · form4-06102021_050612.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-08 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2021 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 8, 2022 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 26, 2021 23:52 UTC | PALISADE BIO, INC. SNCA · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-002776 · ownership.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F2 · security: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · shares: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F2 · shares: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · derivative.exercise_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F1 · derivative.expiration_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. Read SEC document |
| May 12, 2020 Filed May 19, 2020 18:54 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001179110-20-006345 · edgar.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2030-05-12 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2020 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on May 12, 2021 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:32 UTC | PALISADE BIO, INC. SNCA · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-002464 · ownership.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F2 · security: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · shares: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F2 · shares: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · derivative.exercise_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F3 · derivative.expiration_date: N/A Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 21:33 UTC | PALISADE BIO, INC. CUR · Entity 5803 | GrantCommon Stock Purchase Option · Derivative | 187,510 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001171843-19-004415 · ownership.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,510 Underlying: Common Stock · 187,510 shares Expires 2029-07-01 F1 · security: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. F1 · derivative.exercise_date: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. Read SEC document |
| July 01, 2019 Filed Oct 11, 2019 23:25 UTC Amendment | PALISADE BIO, INC. CUR · Entity 5803 | GrantCommon Stock Purchase Option · Derivative | 10,106 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001171843-19-006481 · ownership.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,106 Underlying: Common Stock · 10,106 shares Expires 2029-07-01 F1 · security: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. F3 · security: This amendment is being filed to correct a scrivener's error with regard to the option amount previously reported. F2 · derivative.exercise_price: All exercise prices and share amounts reported in this Form 4/A reflect a 1-for-20 reverse split that occurred on July 17, 2019. F2 · shares: All exercise prices and share amounts reported in this Form 4/A reflect a 1-for-20 reverse split that occurred on July 17, 2019. F3 · shares: This amendment is being filed to correct a scrivener's error with regard to the option amount previously reported. F1 · derivative.exercise_date: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 16:03 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001179110-19-007275 · edgar.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2029-06-04 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2019 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 4, 2020 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 17:36 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001179110-19-004897 · edgar.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2029-04-08 F1 · derivative.exercise_date: The option was granted under the Issuer's 2013 Stock Incentive Plan. The option vests and becomes exercisable over a three-year period commencing on April 8, 2019. Thirty-three percent (33%) of the underlying shares vest and become exercisable on April 8, 2020 (first anniversary of the date of grant) with the balance of the underlying shares vesting in eight equal quarterly installments over the remaining two years of the three-year period, subject to continued service with the Issuer. The option automatically becomes exercisable in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:29 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerCommon Stock | 36,109 | $11.50 | $415,253.50 |
DisclosureSEC source: 0001209191-18-046804 · doc4.xml · nonDerivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2 · shares: Includes 8,910 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 8,910 restricted stock units was cancelled in exchange for the Offer Price. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:50 UTC | PALISADE BIO, INC. CUR · Entity 5803 | GrantCommon Stock Purchase Option · Derivative | 59,660 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001171843-18-005067 · formfour.xml · derivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,660 Underlying: Common Stock · 59,660 shares Expires 2028-07-02 F1 · security: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/18, 12/31/18, 3/31/19, and 6/30/19. F1 · derivative.exercise_date: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/18, 12/31/18, 3/31/19, and 6/30/19. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 17:49 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantCommon Stock, par value $0.01 | 8,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043437 · doc4.xml · nonDerivative · entry 1 Csimma Cristina · CIK 0001501623 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,109 F1 · shares: This restricted stock unit award shall vest in full immediately prior to the 2018 annual shareholders meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.